利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

91 条记录 (耗时 0.045 秒)

    METHODS FOR ASSESSING THE RISK OF ADVERSE EVENTS UPON TREATMENT WITH IGG4 ANTIBODIES
    32.
    发明申请
    METHODS FOR ASSESSING THE RISK OF ADVERSE EVENTS UPON TREATMENT WITH IGG4 ANTIBODIES 审中-公开
    IGG4抗体治疗不良事件的风险评估方法

    公开(公告)号：US20110086366A1

    公开(公告)日：2011-04-14

    申请号：US12918768

    申请日：2009-02-20

    申请人： Aran Frank Labrijn ,  Janine Schuurman ,  Jan Van De Winkel ,  Paul Parren

    发明人： Aran Frank Labrijn ,  Janine Schuurman ,  Jan Van De Winkel ,  Paul Parren

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6854 ,  G01N2800/50 ,  Y02A50/53

    摘要： The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies.

    摘要翻译： 本发明涉及用于评估个体在用能够进行Fab-臂交换的治疗性抗体治疗后发展不良事件的风险的方法和试剂盒，所述方法包括以下步骤：a）从 作为用所述治疗性抗体治疗的候选者的个体，b）测定所述样品是否存在结合已知或怀疑与所述不良事件的致病因子相关联的抗原的循环IgG4抗体，以及c） 步骤b）的测定结果的基础，个体在用治疗性抗体治疗后将发展出所述不良事件的风险，其中所述不良事件发展的风险随着所述循环IgG4抗体水平的增加而增加。

    Non-Human mammalian Arthritis Model Featuring Human Antibodies Against Citrul-Linated Proteins
    37.
    发明申请
    Non-Human mammalian Arthritis Model Featuring Human Antibodies Against Citrul-Linated Proteins 审中-公开
    非人类哺乳动物关节炎模型，具有针对柑橘色素蛋白的人类抗体

    公开(公告)号：US20090117584A1

    公开(公告)日：2009-05-07

    申请号：US11922990

    申请日：2006-06-29

    申请人： Rene Toes ,  Thomas Huizinga ,  Miranda Molenaar ,  Paul Parren ,  Jan Van De Winkel

    发明人： Rene Toes ,  Thomas Huizinga ,  Miranda Molenaar ,  Paul Parren ,  Jan Van De Winkel

    IPC分类号： G01N33/53 ,  A01K67/00

    CPC分类号： G01N33/5088

    摘要： Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis).

    摘要翻译： 使用非人哺乳动物疾病模型，其中所述非人哺乳动物已经植入人滑膜组织或其它含有抗CCP（环状瓜氨酸化肽）抗体产生细胞的人发炎组织，用于（i）分析疾病中的细胞过程 与所述人滑膜组织或其他人发炎组织中的抗CCP抗体相关，（ii）研究抗CCP抗体在与抗CCP抗体相关的疾病的诱导和进展中的作用，（iii）测试抗CCP抗体 用于预防或治疗与抗CCP抗体相关的疾病的治疗剂，和（iv）鉴定可用于预防或治疗与抗CCP抗体相关的疾病的治疗剂。 在一个实施方案中，非人哺乳动物疾病模型是小鼠，例如SCID小鼠，并且与抗CCP抗体相关的疾病是关节炎，例如RA（类风湿性关节炎）。